The Rising Influence of Minor Cannabinoids in Illinois’ Edibles Market
As the cannabis industry grows, innovators are increasingly testing the waters with minor cannabinoids—compounds like CBN, CBC, and CBG. One minor cannabinoid that’s been garnering attention is Δ9-Tetrahydrocannabivarin, or THCV.
In the cannabis community, THCV has earned the moniker “diet weed” for its supposed appetite suppression effects. However, emerging evidence appears to support popular opinion: According to recent studies, THCV could have major impacts on satiety, glycemic control, and energy metabolism.
For cannabis brands looking to market something new and exciting to customers, this is major.
In this guide, we’ll explain why today’s product developers should care about THCV and how they can position THCV-forward products for commercial success. We’ll also flesh out a few myths to look out for and explain how today’s companies can leverage FloraWorks products and expertise in the ever-changing cannabis landscape.
Current THCV Knowledge and Potential Avenues for Product Development
Cannabis researchers already know that THCV shows potential for curbing appetite, improving focus, and supporting weight loss. But how can today’s product innovators leverage this intel to appeal to consumers?
Let’s quickly sum up what investigators have recently learned about THCV:
- Various animal studies have demonstrated THCV’s potential to decrease appetite.
- THC and THCV have very different impacts on one of the two key receptors in the endocannabinoid system (ECS): When THC stimulates the ECS receptor CB1, users might feel the urge to eat. Instead of stimulating the CB1 receptor, THCV blocks this receptor, thus decreasing appetite.
- In addition to suppressing appetite, THCV also shows promise for increasing satiety—feeling full after eating.
- In a 2016 pilot study of 62 subjects with Type 2 diabetes, THCV reduced fasting blood glucose, indicating a degree of restored insulin response.
For cannabis product developers, THCV’s potential for appetite suppression is reason enough to consider introducing THCV-forward formulas. In a wellness landscape where the global market for weight loss supplements is clocking in at over $33 billion, naturally-derived appetite suppression tools are at the forefront of consumer awareness.
By exploring THCV formulas, data-driven brands have an immense opportunity to capitalize on cannabis breakthroughs.
Focus and Energy
A recent study demonstrated increased energy expenditure in mouse models after the administration of plant-based THCV. A small 2015 study might hint at why THCV users feel more energized after dosing, too:
Study participants (healthy males who regularly used THC) reported that combining THCV with THC reduced some of the typical effects of THC intoxication. While mechanisms aren’t crystal clear yet, there’s a potential connection between THCV administration and perceived energy level.
At the height of “hustle culture,” focus and energy are hot topics for consumers. People are looking for new ways to harness their full potential and increase their productivity:
- Stimulant prescriptions are consistently on the rise.
- Energy-boosting supplements alone are an $80 billion+ industry as of 2021.
- Year-over-year, people are cutting back on sleep and increasing time spent at work.
With the rise of THCV, product developers have a chance to build awareness among canna-curious consumers looking to boost their energy. In addition, showcasing energy-boosting cannabis products is an opportunity to invest in consumer education—a chance to show people that “weed” is so much more than THC.
Multiple studies exploring the impacts of THCV on appetite and insulin response have noted that THCV—because of its impacts on satiety, appetite, and energy expenditure—could be a promising treatment for obesity.
We explored these effects above, but let’s consider why THCV might be such an attractive alternative to other obesity treatments compared to traditional weight management drugs:
- It’s well-tolerated – Both mouse and human studies report that THCV is well-tolerated by test subjects. This isn’t always the case with traditional weight loss medications, which produce side effects ranging from intestinal distress to irregular menstrual periods.
- It’s not psychoactive – While THCV is a cannabinoid, it doesn’t produce psychoactive effects.
In addition to being consumer attractants, these two features demonstrate why today’s cannabis formulators should be watching THCV with rapt attention. While brands have thoroughly marketed potential pain relief and mood-boosting benefits of cannabis extensively, THCV offers an opportunity to bring something wholly unique to the market—and impact the conversation about cannabis at large.
Debunking Myths About THCV
Unlike its close relative THC, THCV does not produce intoxicating effects. But this isn’t the only myth that cannabis brands should be aware of if they introduce THCV into their formulas. Let’s break down a few other misconceptions about this minor cannabinoid:
- THC and THCV are distinct compounds – In the interest of consumer education, customers need to understand that THCV and THC are entirely different chemicals with distinct potential.
- THCV likely isn’t habit-forming – While studies on minor cannabinoids are limited, researchers generally believe that non-THC cannabinoids have low (if any) addiction potential. This could be highly attractive to consumers with limited cannabis knowledge looking for pharmaceutical alternatives.
- THCV is becoming more accessible in isolate form – While THCV isolates weren’t widely accessible in the past, the cannabis landscape is changing. As user and clinical interest in minor cannabinoids increases, cannabis manufacturers and brands are responding to market demand with increased availability of specialized formulas. It’s easier than ever before to buy THCV isolate, and THCV formulas will inevitably become mainstream for consumers.
Growth-Centric Partnership: How FloraWorks Supports Your Success
Whether you’re searching for THCV isolate for sale to develop an exciting new consumer offer or supply an upcoming clinical trial, you need a science-focused partner for minor cannabinoid products.
Enter FloraWorks. We’re not your everyday cannabis partner—we offer both:
- Lab-verified, consistent cannabinoid isolates
- Immense experience in the cannabis industry at large
Both of these are critical assets for cannabis product developers, scientific investigators, and all of our partners. As a FloraWorks partner, you have access to:
- Formulation suggestions – We’ll help you craft distinctive products that cater to evolving consumer demands (including formulas with THCV).
- Compliance assistance – Cannabis regulations are ever-shifting—that’s why you need a partner who can help you navigate the sometimes unclear regulatory tides.
- Market trend analysis – As technologies and insights in the cannabis sector continue to shift, FloraWorks can help today’s cannabis brands stay on the cutting edge of research, products, and market demand.
FloraWorks delivers both top-quality products and bona fide expertise. When you need multifaceted support for your cannabis brand, we’re a partner you can depend on.
THCV: Minor Cannabinoid, Major Potential
In short, THCV has shown early clinical potential for appetite management, energy production, and even weight loss—and this widespread research investment is evidence enough that THCV is the next big isolate slated to shake up our industry.
It’s time to get in on the ground floor of THCV formulation, and FloraWorks can help. Our cannabinoid isolates are lab-tested and independently verified: cannabis innovators can use our products with confidence. And when you need regulatory or R&D support, our expert team is always ready to lend our insights.
If you’re looking for a strategic partner in all things cannabis, let’s start a conversation.
Frontiers in Pharmacology. Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669157/
Journal of Cannabis Research. Δ9-Tetrahydrocannabivarin (THCV): A Commentary on Potential Therapeutic Benefit for the Management of Obesity and Diabetes. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819335/
British Journal of Pharmacology. Synthetic and Plant-Derived Cannabinoid Receptor Antagonists Show Hypophagic Properties in Fasted and Non-Fasted Mice. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697695/
Nutrition and Diabetes. The Cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) Ameliorates Insulin Sensitivity in Two Mouse Models of Obesity. https://pubmed.ncbi.nlm.nih.gov/23712280/
American Diabetes Association. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. https://diabetesjournals.org/care/article/39/10/1777/129/Efficacy-and-Safety-of-Cannabidiol-and
Grandview Research. Weight Loss Supplements Market Size, Share & Trends Analysis Report By End User (18-40 Years, Under 18 Years), By Distribution Channel (Offline, Online), By Type (Powders, Pills), By Ingredient, And Segment Forecasts, 2021 – 2028. https://www.grandviewresearch.com/industry-analysis/weight-loss-supplements-market-report
Journal of Psychopharmacology. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. https://pubmed.ncbi.nlm.nih.gov/26577065/
US Centers for Disease Control and Prevention. Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults — United States, 2016–2021. https://www.cdc.gov/mmwr/volumes/72/wr/mm7213a1.htm
Allied Market Research. Energy Supplement Market by Product Type (Energy Drinks, Energy Gels, Energy Bars, Gummies, Others), by End User (Kids, Adults, Teenagers), by Sales Channel (Hypermarkets and Supermarkets, Convenience Stores, Specialty Stores, Online Sales Channel): Global Opportunity Analysis and Industry Forecast, 2021-2031. https://www.alliedmarketresearch.com/energy-supplement-market-A16879
American Academy of Sleep Medicine. Many US Workers Are Sleeping Less to Work More. https://sleepeducation.org/many-workers-sleeping-less-work-more/
Medline Plus. Orlistat. https://medlineplus.gov/druginfo/meds/a601244.html
National Institutes of Health. Notice of Special Interest (NOSI): Promoting Mechanistic Research on Therapeutic and Other Biological Properties of Minor Cannabinoids and Terpenes. https://grants.nih.gov/grants/guide/notice-files/NOT-AT-22-027.ht